circulating tumor DNA
Foresight Diagnostics Commercializing PhasED-Seq Liquid Biopsy Tech for Improved MRD Detection
Premium
The technology, developed by researchers at Stanford, showed strong performance in a new study of lymphoma, and early data for solid tumors is already available.
Natera Minimal Residual Disease Test Predicts Oligometastatic CRC Patient Outcomes in New Study
Premium
Investigators analyzed blood samples from patients at two time points after curative-intent surgery, finding that ctDNA MRD status was highly predictive of outcome.
A new publication detailing ctDNA testing results has spurred a minimal residual disease biomarker-directed trial for Roche's atezolizumab in bladder cancer.
Liquid Biopsy MRD Research at ASCO Showcases Uses in Variety of Tumor Types, Indications
Research presented at the ASCO meeting described efforts to expand the use of existing technologies into new directions.
Liquid Biopsy-Guided EGFR Rechallenge Therapy Shows Benefit for Colorectal Cancer Patients
The first interventional trial to use ctDNA to recruit eligible patients for this treatment showed 30 percent observable responses and more than 60 percent disease control.